The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk

March 30, 2026 updated by: Ameen Salahudeen, University of Illinois at Chicago

Systemwide Early Notification Tool for ImmineNt Lung Cancer-1 Study: Evaluating Patient-Reported Outcomes of Artificial Intelligence Inferred Lung Cancer Risk

This is a two-cohort (screen naïve vs screen established), prospective, longitudinal, single-center clinical study design that will provide data to comprehensively evaluate patient-reported outcomes of Artificial Intelligence (AI) based prediction of an individual's risk of developing lung cancer over the next 3 years.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a prospective, longitudinal, single-center interventional study of AI lung cancer prediction tests with return of results at the University of Illinois Hospital clinics. The purpose is to evaluate patient-reported outcomes of AI risk inference. The motivation for the study was based on findings that existing AI tests have been designed without including patient populations like those at UI Health. Using newer, more generalizable AI tests, UI Health researchers will evaluate patient perceptions of AI risk and how that impacts their beliefs about their health and lung cancer screening.

The study will enroll up to 200 screen-naïve and up to 200 screen-established participants, at least 100 and no more than 400 participants, as defined by the eligibility criteria, over an anticipated enrollment period of approximately 12 months. Recruitment strategies to identify potential participants may include identification of participants through electronic health records, emails, recruitment campaigns, and other outreach strategies.

Two cohorts will be studied:

A) Individuals eligible for lung cancer screening by the USPSTF who have never undergone lung cancer screening with low-dose CT will receive a regulatory cleared laboratory developed test for lung cancer screening eligible patients.

B) For USPSTF-eligible individuals who have already received low-dose CT screening, these individuals will receive a research-use-only (RUO) multimodal AI risk prediction that has been validated on UI Health patients. Multimodal AI risk prediction was developed by UIC researchers to predict long-term lung cancer risk by AI inference of lung screening CT images and clinical characteristics from a diverse patient population.

Study Type

Interventional

Enrollment (Estimated)

400

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Ameen Salahudeen, MD, PhD
  • Phone Number: (312) 355-1625
  • Email: ameen@uic.edu

Study Contact Backup

  • Name: Erica Seltzer, DrPh, MPH
  • Phone Number: (312) 413-7432
  • Email: eseltzer@uic.edu

Study Locations

  • United States
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Recruiting
        • University of Illinois at Chicago

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Participants must be 50-80 years of age, inclusive, at the time of signing the Informed Consent Form (ICF).
  • Participants must be eligible for LDCT screening as defined by the USPSTF
  • USPSTF-eligible patients at UI Health and Mile Square FQHC, including primary care and substance use disorder clinics.
  • Adults who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
  • Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization. Consent provided by a legally authorized representative is not permitted in this protocol.
  • Women of childbearing potential must not be pregnant or breastfeeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.
  • Ability of the subject to understand and comply with study procedures for the entire length of the study.

Exclusion Criteria:

  • Adults who have more than 20 pack-years history but who have not smoked for 15 years or more prior to informed consent (i.e., quit smoking for 15 or more years).
  • Undergoing or referred for diagnostic evaluation due to clinical suspicion for cancer (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality).
  • Personal history of invasive solid tumor or hematologic malignancy, diagnosed within the 5 years prior to the expected enrollment date, or diagnosed greater than 5 years prior to the expected enrollment date and never treated. Individuals with a diagnosis of non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin are not excluded.
  • Prior/Concurrent Concomitant Therapy (Medications/Treatments): Definitive treatment for invasive solid tumor or hematologic malignancy within the 5 years prior to the expected enrollment date. Adjuvant hormone therapy for cancer (e.g., for breast or prostate cancer) is not an exclusion criterion.
  • Individuals who will not be able to comply with the protocol procedures.
  • Individuals who are not currently registered patients at UIH
  • Current pregnancy (by self-report of pregnancy status)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Screen-established cohort
Screen-established participants are individuals who are currently undergoing or have previously undergone LDCT screening. These participants will receive a research-use-only (RUO) multimodal artificial intelligence risk prediction based on lung screening CT imaging and clinical features.
Diagnostic test: Research-use-only multimodal AI risk model
For USPSTF-eligible individuals who have already received low-dose CT screening, these individuals will receive a research-use-only (RUO) multimodal artificial intelligence risk prediction based on lung screening CT imaging and clinical features.
Other: Screen-naïve cohort
In this study, screen-naïve participants are individuals who are eligible for lung cancer screening but have never previously undergone low-dose CT (LDCT) screening. These participants will receive a regulatory cleared laboratory developed test for lung cancer screening, circulating DNA fragmentomics.
Diagnostic test: Artificial Intelligence (AI) test
Individuals eligible for lung cancer screening by the USPSTF who have never undergone lung cancer screening with low-dose CT will receive a regulatory cleared laboratory developed blood test for lung cancer screening, circulating DNA fragmentomics

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Reported Outcomes Measurement Information System (PROMIS) survey results before and following the return of results (ROR)
Time Frame: Day 1 through 30 days post-return of results survey, or approximately Day 60
To evaluate participant reported outcomes before and after return of results (ROR) using the PROMIS test surveys
Day 1 through 30 days post-return of results survey, or approximately Day 60
Multidimensional Impact of Cancer Risk Assessment (MICRA) following return of results (ROR)
Time Frame: Day 1 through 30 days post-return of results survey, or approximately Day 60
To evaluate participants' MICRA score following the return of results (ROR)
Day 1 through 30 days post-return of results survey, or approximately Day 60
Perceptions and health beliefs relating to lung cancer screening using the Lung Health Belief Scale (Lung-HBS) perceived risk and perceived benefits after the return of results (ROR)
Time Frame: Day 1 through 30 days post-return of results survey, or approximately Day 60
To evaluate the perceptions and health beliefs of participants related to lung cancer screening
Day 1 through 30 days post-return of results survey, or approximately Day 60

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rates of participant adherence to LDCT and smoking cessation within one year of return of results (ROR).
Time Frame: Screening through 1 year post-return of results
To evaluate rates of participant adherence to LDCT and smoking cessation which will be measured as the proportion of patients who utilize low dose CT (LDCT) screening in both screening naïve and screening established cohorts within 1 year of ROR, and the proportion who cease smoking 1 year after ROR.
Screening through 1 year post-return of results

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Illinois at Chicago

Investigators

  • Principal Investigator: Ameen Salahudeen, MD, PhD, University of Illinois at Chicago

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 11, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

January 1, 2029

Study Registration Dates

First Submitted

January 6, 2026

First Submitted That Met QC Criteria

March 4, 2026

First Posted (Actual)

March 9, 2026

Study Record Updates

Last Update Posted (Actual)

April 6, 2026

Last Update Submitted That Met QC Criteria

March 30, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-0860

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Cancer

Clinical Trials on Research-use-only multimodal AI risk model

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe